Last reviewed · How we verify

pazopanib or guideline conform chemotherapy

GWT-TUD GmbH · FDA-approved active Small molecule

Pazopanib is a multi-targeted tyrosine kinase inhibitor that blocks angiogenesis and tumor cell proliferation by inhibiting VEGFR, PDGFR, and c-Kit signaling.

Pazopanib is a multi-targeted tyrosine kinase inhibitor that blocks angiogenesis and tumor cell proliferation by inhibiting VEGFR, PDGFR, and c-Kit signaling. Used for Advanced renal cell carcinoma, Advanced soft tissue sarcoma, Ovarian cancer (in combination with chemotherapy).

At a glance

Generic namepazopanib or guideline conform chemotherapy
SponsorGWT-TUD GmbH
Drug classMulti-targeted tyrosine kinase inhibitor
TargetVEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, c-Kit
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Pazopanib inhibits multiple receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-α and -β), and c-Kit. By blocking these pathways, it reduces tumor blood vessel formation (angiogenesis) and directly inhibits cancer cell growth and survival. The guideline-conform chemotherapy component refers to standard cytotoxic chemotherapy regimens used as comparative or alternative treatment options.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: